Showing results (61-70 of 232) with videos related to
Sort By:
Pageof 24
The European Respiratory Journal|June 13, 2001
Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapyA Lubasch, R Erbes, H Mauch, et al.Drugs of Today (Barcelona, Spain : 1998)|July 25, 2003
Clinical results in the treatment of respiratory infections with moxifloxacinH Lode, A Lubasch, M Raffenberg, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 13, 2001
Meropenem: clinical response in relation to in vitro susceptibilityG L Drusano, H Lode, J R EdwardsDeutsche Medizinische Wochenschrift (1946)|April 22, 1977
[Bacterial endocarditis. Clinical picture, treatment and course in 37 patients (author's transl)]H Lode, B Behn, H Langmaack, et al.Advances in Clinical Pharmacology|January 1, 1978
[Pharmacologic studies or aminoglycoside antibiotics (amikacin, gentamicin, sisomicin, tobramycin)]H Lode, K Grunert, B Kemmerich, et al.Pneumologie (Stuttgart, Germany)|July 20, 1999
[Inpatient treatment costs of exacerbated chronic obstructive lung disease]K Riecke, J Eller, C Gericke, et al.The Journal of Antimicrobial Chemotherapy|July 1, 1993
Diagnostic problems in lower respiratory tract infectionsH Lode, T Schaberg, M Raffenberg, et al.The Journal of Infectious Diseases|November 1, 1976
Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibioticH Lode, K Grunert, P Koeppe, et al.The American Review of Respiratory Disease|June 1, 1993
Increased number of alveolar macrophages expressing surface molecules of the CD11/CD18 family in sarcoidosis and idiopathic pulmonary fibrosis is related to the production of superoxide anions by these cellsT Schaberg, M Rau, H Stephan, et al.Deutsche Medizinische Wochenschrift (1946)|September 3, 1976
[Pharmacokinetics and clinical experience with amikacin. A new aminoglycoside antibiotic]H Lode, K Grunert, P Koeppe, et al.Pageof 24